首页> 外文会议>International Conference on Big Data Analytics >Big Data Analytics Advances in Health Intelligence, Public Health, and Evidence-Based Precision Medicine
【24h】

Big Data Analytics Advances in Health Intelligence, Public Health, and Evidence-Based Precision Medicine

机译:健康智力,公共卫生和基于证据的精密药物的大数据分析进展

获取原文

摘要

Large amount of patient data is available in hospitals. Moreover, a huge body of medical knowledge is available in digital form in the public domain, like NLM (National Library of Medicine), PubMed, NCBI (National Center for Biotechnology Information), MeSH (Medical Subject Heading), OMIM (Online Mendelian Inheritance in Man). There are also public biomedical databases like PDB (Protein Data Bank), GO (Gene Ontology), Chemical Entities of Biological Interest (ChEBI), KEGG (Kyoto Encyclopedia of Genes and Genomes), Drug databases (DrugBank), Recon (Reconstruction of Human Metabolism), dbSNP (DNA Mutation Database), COSMIC (Catalogue of Somatic Mutations in Cancer), etc. The list goes on and on and on. In this paper, we are addressing the challenge - how does our analytic solution combine these data and knowledge bodies through the technology of big-data combined with artificial intelligence, mathematical models, and translational medicine into "Evidence Based Precision Medicine - the perfect decision outcome with perfect knowledge backing." The benefits are immense for many stakeholders. Payer costs are reduced significantly - be it an insurance company or employer or an uninsured individual. The accuracy of medical decisions including the hospital productivity are increased significantly, with reduced medical errors, reduced disease burden, reduced fraud and wastage. Evidence based precision medicine will benefit patients, patients' families, doctors, hospitals, insurance companies, payers, Government regulators, healthcare professionals, public exchequers and finally, improve the overall general health of the population as a whole.
机译:医院提供大量患者数据。此外,在公共领域的数字形式中有一个巨大的医学知识,如NLM(国家医学图书馆),NCBI(国家生物技术信息中心),网格(医学主题标题),OMIM(在线孟德梅的继承在人类)。还有PDB(蛋白质数据库)等公共生物医学数据库,Go(基因本体论),生物利益化学实体(Chebi),Kegg(基因和基因组的京都百科全书),药物数据库(药物银行),侦察(人类重建新陈代谢),DBSNP(DNA突变数据库),宇宙(癌症中体细胞突变的目录)等。列表继续和打开。在本文中,我们正在解决挑战 - 我们的分析解决方案如何通过大数据与人工智能,数学模型和翻译医学联合“基于证据的精密药”结合这些数据和知识机构将这些数据和知识机构结合在一起“完美的决策结果”完美的知识支持。“许多利益攸关方的利益是巨大的。付款人成本明显减少 - 是保险公司或雇主或未保险的个人。包括医院生产力的医学决策的准确性显着增加,减少医疗误差,降低疾病负担,减少欺诈和浪费。基于证据的精密药物将受益患者,患者家属,医生,医院,保险公司,付款人,政府监管机构,医疗专业人士,公共货币,最后,提高整体人口的总体健康。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号